Low Level of Circulating Activated Protein C Is a Risk Factor for Venous Thromboembolism

Summary

The levels of circulating activated protein C (APC) reflect in vivo protein C activation. The aim of this study was to determine whether a low APC level is an independent risk factor for venous thromboembolism (VTE). We measured APC in 160 patients with a history of VTE and without recognized thrombophilic defects, and in 199 healthy individuals. The mean (±SD) APC level was lower in patients (0.99 ± 0.44 ng/ml) than in controls (1.19 ± 0.41 ng/ml) (p <0.0001), and showed a different distribution in the two groups. Thirty-eight patients (23.7%) had APC levels below the 5th percentile of the control group (<0.69 ng/ml) and 57 patients (35.6%) had APC levels below the 10th percentile (<0.77 ng/ml). APC levels <0.69 ng/ml increased the risk of a single or recurrent episode of VTE 4.2-fold (95% confidence interval, 2.0-9.0) or 6.9-fold (2.6-17.9), respectively, and APC levels <0.77 ng/ml increased these risks 3.4-fold (1.9-6.2) or 5.1-fold (2.3-11.2), respectively, compared with controls. Familial studies revealed that in some cases the low APC phenotype seems to be hereditary. We conclude that a low level of circulating APC in individuals without any of the most recognized thrombophilic defects is a prevalent, independent risk factor for VTE, and that it predisposes to recurrent VTE.

Keywords

Thromboembolism - protein C - activated protein C - venous thrombosis - risk factor

• References

• 1 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3.
• 2 Schwartz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-300.
• 3 Dahlback B, Carlsson M, Svenson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
• 4 Bertina R, Koeleman B, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 5 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia. Pathogenesis, clinical syndromes and management. Blood 1996; 87: 3531-44.
• 6 Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119: 819-27.
• 7 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis of venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 8 Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 9 Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35.
• 10 Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000; 83: 639-43.
• 11 España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays. Enzyme levels are proportional to total protein C levels. Thromb Haemost 1996; 75: 56-61.
• 12 Frezzato M, Tosetto A, Rodeghiero E. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Amer J Epidemiol 1996; 143: 1257-65.
• 13 España F. Complexes of activated protein C with its inhibitors. In: Protein C pathway. Aznar J, España F. eds. Barcelona: Springer-Verlag; 1991: 61-75.
• 14 Hendl S, España F, Aznar J, Estellés A, Gilabert J. Functional and immuno-logical determination of protein C by immunosorbent assays. Rev Iberoamer Tromb Hemost 1991; 4: 16-20.
• 15 España F, Hendl S, Gilabert J, Estellés A, Aznar J. Evaluation of two functional assays for the measurement of protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) activity. Thromb Res 1993; 70: 375-84.
• 16 España F, Estellés A, Aznar J, Gilabert J. Assay of protein C in human plasma: Comparison of amidolytic, coagulation and immunochemical assays. Thromb Res 1986; 44: 771-82.
• 17 Woolf B. On estimating the relation between blood group and disease. Ann Hum Gen 1995; 19: 251-3.
• 18 Cattaneo M, Franchi F, Zighetti ML, Martinelli I, Asti D, Mannucci PM. Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism. Relationships with plasma homocysteine levels. Arterioscler Thromb Vasc Biol 1998; 18: 1371-5.
• 19 Öhlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85: 330-6.
• 20 Öhlin A-K, Marlar RA. Thrombomodulin gene defects in families with thromboembolic disease. A report on four families. Thromb Haemost 1999; 81: 338-44.
• 21 Merati G, Biguzzi F, Oganesyan N. et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis [abstract]. Thromb Haemost. 1999 (Suppl: Aug 1999): 507.
• 22 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang UN. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
• 23 Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-92.
• 24 Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
• 25 Faioni EM, Franchi F, Asti D, Mannucci PM. Activation of the protein C pathway in hereditary thrombophilia. Thromb Haemost 1998; 80: 557-60.
• 26 Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.